Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist

被引:99
|
作者
Arend, WP [1 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Rheumatol, Denver, CO 80262 USA
关键词
rheumatoid arthritis; interleukin-l; interleukin-l receptor antagonist; cytokines;
D O I
10.1053/sarh.2001.23693
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To summarize the role of cytokine imbalance in the pathogenesis of rheumatoid arthritis. Methods: The literature on cytokines in rheumatoid arthritis from American and European medical journals was reviewed. Results: An important role of interleukin (IL)-1 and tumor necrosis factor (TNF)-alpha in the mediation of tissue damage in the rheumatoid joint has been well established over the past 10 years. The IL-1 family consists of 2 agonists, IL-1 alpha and IL-1 beta, and a specific naturally occurring receptor antagonist, IL-1Ra. Both forms of IL-1 induce intracellular responses through binding to the type 1 IL-1 receptor (IL-1R) on target cells. IL-1Ra binds to IL-1R with an avidity equal to that of IL-1 but fails to stimulate the cells, thus functioning as an inhibitor of IL-1 binding. Endogenous production of IL-1Ra is an important anti-inflammatory mechanism both in animal models of disease and in human disease. In the rheumatoid synovium, an imbalance exists in this system, because the relative levels of production of IL-1Ra are not adequate to effectively block the proinflammatory effects of IL-1. Studies in different animal models of inflammatory arthritis indicate that a deficiency of IL-1Ra relative to IL-1 leads to more severe disease and even to the spontaneous development of arthritis as observed in IL-1Ra knockout mice. A restoration of the balance between IL-1Ra and IL-1 in human disease can theoretically be achieved through the administration of recombinant IL-1ra protein, gene therapy with the IL-1Ra complementary DNA, or stimulation of production of endogenous IL-1Ra. Conclusions: An imbalance between proinflammatory cytokines and cytokine antagonists or inhibitors may be one factor predisposing to initiation or perpetuation of rheumatoid synovitis. Semin Arthritis Rheum 30:1-6 (Suppl 2). Copyright (C) 2001 by W.B. Saunders Company.
引用
下载
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [21] Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis
    Barrera, P
    van der Laken, CJ
    Boerman, OC
    Oyen, WJG
    van de Ven, MTP
    van Lent, PLEM
    van de Putte, LBA
    Corstens, FHM
    RHEUMATOLOGY, 2000, 39 (08) : 870 - 874
  • [22] INTERLEUKIN-1 RECEPTOR ANTAGONIST: RELATION TO CARDIOVASCULAR DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Almeida, C.
    Quevedo-Abeledo, J. C.
    Caceres Martin, L.
    Hernandez Hernandez, V.
    Delgado-Gonzalez, A.
    Ferraz-Amaro, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1166 - 1166
  • [23] The Prospect of Treating Rheumatoid Arthritis with Recombinant Human Interleukin-1 Receptor Antagonist
    Barry Bresnihan
    BioDrugs, 2001, 15 : 87 - 97
  • [24] Interleukin-1 β and interleukin receptor antagonist gene polymorphisms:: Relationship to occurrence and severity of rheumatoid arthritis
    Navaux, F
    Lescoulie, PL
    Constantin, A
    Mazières, B
    Cantagrel, A
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S64 - S64
  • [25] INTERLEUKIN-1, INTERLEUKIN-1 RECEPTOR, AND INTERLEUKIN-1 RECEPTOR ANTAGONIST
    ESPAT, NJ
    ROGY, MA
    COPELAND, EM
    MOLDAWER, LL
    PROCEEDINGS OF THE NUTRITION SOCIETY, 1994, 53 (02) : 393 - 400
  • [26] Mucosal imbalance of interleukin-1β and interleukin-1 receptor antagonist in canine inflammatory bowel disease
    Maeda, Shingo
    Ohno, Koichi
    Nakamura, Kenji
    Uchida, Kazuyuki
    Nakashima, Ko
    Fukushima, Kenjiro
    Tsukamoto, Atsushi
    Goto-Koshino, Yuko
    Fujino, Yasuhito
    Tsujimoto, Hajime
    VETERINARY JOURNAL, 2012, 194 (01): : 66 - 70
  • [27] Interleukin-1 receptor antagonist gene polymorphism: A susceptibility factor to rheumatoid arthritis.
    Carreira, PE
    GonzalezCrespo, MR
    Pablos, JL
    Santiago, B
    Ciruelo, E
    delaCamara, AG
    GomezReino, JJ
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 763 - 763
  • [28] The Clinical Significance of Interleukin-1 Receptor Antagonist+2018 Polymorphism in Rheumatoid Arthritis
    Ismail, Endom
    Nofal, Omimah Khaled Jaber
    Sakthiswary, Rajalingham
    Shaharir, Syahrul Sazliyana
    Sridharan, Radhika
    PLOS ONE, 2016, 11 (04):
  • [29] Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist
    Bao, Jun
    Yue, Tao
    Li, Ting
    He, Dong-Yi
    Bao, Yi-Xiao
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (04) : 370 - 376
  • [30] Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis.
    Nuki, G
    Rozman, B
    Pavelka, K
    Emery, P
    Lookabaugh, J
    Musikic, P
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1159 - 1159